Loading...
10 China Cardiovascular Drugs Reports
Country Covered: China
Study Period: 2019 - 2030
Major Players: Amgen, Novartis, Boehringer Ingelheim, Pfizer, Baxter
Country Covered: China
Study Period: 2019 - 2030
Major Players: Amgen, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Bayer
Country Covered: China
Study Period: 2019 - 2030
Major Players: Boehringer Ingelheim, Bristol-Myers Squibb, Roche, Johnson & Johnson, Pfizer
Country Covered: China
Study Period: 2019 - 2030
Major Players: AstraZeneca, Bayer, Sanofi, Merck, Novartis
Country Covered: China
Study Period: 2021 - 2030
Major Players: AstraZeneca, Novartis, Pfizer, Bayer, Kowa
Country Covered: China
Study Period: 2019 - 2030
Major Players: Koninklijke Philips, Abbott Laboratories, Medtronic, Boston Scientific, Novartis
Country Covered: China
Study Period: 2019 - 2030
Major Players: Medtronic, LimFlow, Cardiovascular Systems, Eli Lilly and Company, Abbott Laboratories
Country Covered: China
Study Period: 2019 - 2030
Major Players: Mylan, Teva Pharmaceutical Industries, Pfizer, Sanofi, Upsher-Smith Laboratories
Country Covered: China
Study Period: 2019 - 2030
Major Players: Pfizer, Nuray Chemicals Private Limited, Dr. Reddy’s Laboratories
Country Covered: China
Study Period: 2019 - 2030
Major Players: Zensun Shanghai Sci & Tech, Capricor Therapeutics, Vericel, AstraZeneca, Pfizer